Clinical Trial

Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart. Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-22.
Trial Details
NCT Number NCT07147751
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Conditions Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)
Enrollment 100 participants
Start Date 2026-09
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-22